gms | German Medical Science

82nd Annual Meeting of the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery

German Society of Oto-Rhino-Laryngology, Head and Neck Surgery

01.06. - 05.06.2011, Freiburg

Article

Send article

Results of hearing restoration in NF2 patients with CI, ABI, PABI and AMI

Meeting Abstract

Search Medline for

  • corresponding author Minoo Lenarz - Hals-Nasen-Ohrenklinik, Charité - Universitätsmedizin Berlin, Berlin, Deutschland

Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie. 82. Jahresversammlung der Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie. Freiburg i. Br., 01.-05.06.2011. Düsseldorf: German Medical Science GMS Publishing House; 2011. Doc11hnod399

doi: 10.3205/11hnod399, urn:nbn:de:0183-11hnod3998

Published: April 19, 2011

© 2011 Lenarz.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.

Outline

Text

Introduction: Most of the NF2 patients develop bilateral deafness, which is due to growth or surgical removal of vestibular schwannomas. Depending on the degree of neuronal damage, only a minority of NF2 patients may benefit from hearing restoration with a cochlear implant. The majority, however, require a central auditory prosthesis, which bypasses the damaged auditory nerve and stimulates directly the central auditory pathways.

Methods: The results of hearing restoration in adult NF2 patients with 4 different types of auditory prostheses (cochlear implant, auditory brainstem implant, Penetrating auditory brainstem implant and auditory midbrain implant) will be compared.

Results: The potential influencing factors on the performance of these different auditory prostheses in NF2 subjects will be discussed.

Conclusion: The present state of the art in hearing restoration in NF2 patients and future directions in research and development of central auditory prostheses will be presented.

Supported by: DFG-SFB 599 and Cochlear Corporation, Lane Cove, Australia.